|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
149.73 Million
|
|
CAGR
(2025-2030)
|
3.11%
|
|
Fastest
Growing Segment
|
Magnetic
Resonance Imaging (MRI)
|
|
Largest
Market
|
North
America
|
|
Market
Size (2030)
|
USD
177.86 Million
|
Market Overview
Global Multiple System Atrophy Market was valued at USD 149.73 Million in 2024 and and is expected to reach USD 177.86 Million by 2030 with a CAGR of 3.11% during the forecast period. The global Multiple System Atrophy (MSA) market is experiencing significant expansion due to the growing prevalence of this rare, progressive neurodegenerative disorder and the increasing demand for effective diagnostic and therapeutic solutions. MSA, which involves the degeneration of nerve cells in the brain and affects multiple systems such as motor control, autonomic functions, and coordination, currently lacks a cure, creating a notable unmet need for innovative treatments and diagnostic tools. MSA is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. Symptoms tend to appear in a person's 50s and advance rapidly over the course of five to 10 years. A person with MSA will have increased difficulty with movement and eventually become bedridden. People with MSA often develop swallowing problems that can lead to pneumonia in the later stages of the disease.
Advancements in biomarkers and diagnostic technologies are enhancing early detection and improving the accuracy of MSA diagnoses, which is expected to lead to earlier interventions, better patient outcomes, and the development of targeted therapies. Increasing collaborations between biotechnology firms, research institutions, and healthcare organizations are accelerating the development of MSA-specific treatments, with growing investment in both preclinical and clinical research expected to expand the pipeline of potential therapies.
North America leads the MSA market, driven by robust healthcare infrastructure, rising research and development activities, and heightened patient awareness. However, the main challenges in the market are the absence of a definitive cure and the complexity of treating a multi-system disorder. The rarity of MSA further complicates the development of therapies and diagnostic tools. Nevertheless, advancements in precision medicine, stem cell therapies, and gene editing technologies offer substantial opportunities to transform the treatment landscape. The global MSA market is positioned for steady growth, supported by ongoing scientific progress, increased patient awareness, and the continued pursuit of effective treatments.
Key Market Drivers
Advancements
in Diagnostic Technologies
Advancements in diagnostic technologies
are poised to propel the growth of the Global Multiple System Atrophy (MSA)
Market by enhancing early detection and accuracy in disease diagnosis.
Cutting-edge diagnostic tools, such as advanced imaging techniques and
biomarker identification, enable healthcare professionals to detect MSA at
earlier stages, facilitating timely intervention and management. Accurate and
swift diagnosis is critical in addressing Multiple System Atrophy, a rare
neurodegenerative disorder with diverse clinical presentations. The integration
of innovative diagnostic methods not only aids in precise disease
identification but also contributes to the development of targeted therapeutic
strategies. As these technologies become more sophisticated, they enhance the
overall efficiency of clinical trials, expediting the approval process for
novel MSA treatments. In October 2024, Sunbird Bio announced new data highlighting the effectiveness of its blood biomarker technology in detecting the aggregation of alpha-synuclein (α-synuclein) in the brain through a simple blood draw. The study results, set to be presented in a poster session on October 31 at the Clinical Trials on Alzheimer’s Disease (CTAD) international conference, showcase the potential of Sunbird’s diagnostic technology to accurately identify multiple neurodegenerative diseases, including Parkinson’s disease and multiple system atrophy. These advancements in diagnostic technologies offer the promise of a non-invasive, blood-based approach for diagnosing these conditions, marking a significant step forward in the early detection and accurate diagnosis of neurodegenerative diseases. Improved diagnostic capabilities attract
increased investments in research and development, fostering collaboration
between pharmaceutical companies and healthcare institutions. This synergy
accelerates the development of groundbreaking therapies, fostering a conducive
environment for market growth. In essence, the symbiotic relationship between
diagnostic advancements and therapeutic innovations is set to reshape the
landscape of the Global Multiple System Atrophy Market, creating opportunities
for stakeholders and improving patient outcomes.
Rising
Research and Development Investments
The growth of the Global Multiple System
Atrophy (MSA) Market is poised to be significantly influenced by the upsurge in
Research and Development (R&D) investments. Increased financial commitments
to R&D initiatives underscore a commitment to advancing our understanding
of MSA and developing novel therapeutic interventions. Pharmaceutical companies
and research institutions are allocating substantial resources to explore
innovative treatment modalities, biomarkers, and diagnostic technologies. In May 2024, an international team of scientists made a groundbreaking discovery, identifying genetic risk factors for multiple system atrophy (MSA), a condition previously thought to have no genetic basis. The study, published in Neuron, involved whole genome sequencing of 888 MSA cases of European ancestry and 7,128 control samples. Researchers pinpointed four loci on the genome significantly linked to MSA development. Additionally, RNA analysis revealed that mutations in the USP38-DT, KCTD7, and lnc-KCTD7-2 genes increased susceptibility to MSA. This study highlights the growing importance of research and development investments in understanding the genetic underpinnings of complex diseases like MSA. Supported by grants from the National Institute on Aging (RF1 AG057474 and U01 AG061356) and the NUgene Project, which provided MSA patient samples, these findings underscore the value of continued funding in advancing scientific knowledge and uncovering new therapeutic targets for neurodegenerative diseases. This discovery could lead to more targeted approaches in both diagnosing and treating MSA, marking a significant milestone in the field of neurogenetics.
Rising
R&D investments contribute to the acceleration of clinical trials,
facilitating the swift development and regulatory approval of potential MSA
treatments. This influx of funds fosters collaboration among industry players,
leading to synergies in expertise and resources. Furthermore, heightened
R&D spending attracts top-tier talent and fosters a culture of innovation
within the scientific community, propelling breakthrough discoveries and
advancements in MSA research. In November 2023, Asklepios BioPharmaceutical, Inc. (AskBio) announced that the first patient had been randomized in the Phase 1 REGENERATE MSA-101 clinical trial of AB-1005, a gene therapy under development for the treatment of multiple system atrophy-parkinsonian type (MSA-P). This marks a key milestone in the advancement of AB-1005, which uses an adeno-associated viral vector to deliver glial cell line-derived neurotrophic factor (AAV2-GDNF) to the putamen. The progression of this clinical trial underscores the growing focus on research and development investments aimed at innovative treatments for neurodegenerative diseases. The trial's progress brings this promising gene therapy closer to potentially offering a new therapeutic option for MSA-P patients, illustrating the vital role of R&D funding in advancing cutting-edge treatments. The positive impact of these investments extends
beyond scientific progress, creating a conducive market environment by boosting
investor confidence and attracting additional funding. In essence, the
escalating R&D investments in the MSA space not only drive scientific
innovation but also play a pivotal role in shaping the future landscape of the
Global Multiple System Atrophy Market, offering hope for improved patient
outcomes and therapeutic solutions.
Collaborative
Initiatives and Partnerships
Collaborative initiatives and
partnerships are set to be key drivers in propelling the growth of the Global
Multiple System Atrophy (MSA) Market. In an era of complex healthcare
challenges, strategic alliances between pharmaceutical companies, research institutions,
and advocacy groups are becoming increasingly prevalent. These partnerships
foster a shared pool of resources, expertise, and data, creating synergies that
accelerate the development of innovative solutions for MSA. Pooling knowledge
and capabilities through collaborations enables faster progress in research and
development efforts, leading to more efficient clinical trials and the timely
introduction of new therapies. Joint initiatives also mitigate risks and
financial burdens, allowing stakeholders to navigate the intricate landscape of
MSA research collectively. Furthermore, collaborative efforts enhance the
credibility and robustness of scientific findings, which is crucial for regulatory
approvals and market acceptance. By establishing a network of shared
objectives, these partnerships create a supportive ecosystem for sustained
advancements, attracting further investments and fostering a competitive yet
cooperative environment within the Global Multiple System Atrophy Market. In
essence, collaborative initiatives are pivotal in driving the industry forward,
ensuring that the collective pursuit of solutions for MSA remains at the
forefront of global healthcare innovation.
Download Free Sample Report
Key Market Challenges
Diagnostic
Complexity and Variability
The growth of the Global Multiple System
Atrophy (MSA) Market may face hindrances due to the diagnostic complexity and
variability inherent in the disease. MSA presents a spectrum of clinical
manifestations that often overlap with other neurodegenerative disorders,
posing challenges in accurate and timely diagnosis. The intricacies and
subtleties of MSA symptoms can lead to misdiagnoses or delayed identification,
impacting the initiation of appropriate treatments. The lack of standardized
diagnostic criteria further contributes to variability in clinical assessments,
hindering the consistency needed for effective research, drug development, and
regulatory processes. This diagnostic uncertainty may deter investment and slow
down the overall pace of innovation within the MSA market, as pharmaceutical
companies and investors may be cautious about the inherent challenges in
navigating such diagnostic complexities. Additionally, the variability in
disease presentation among individuals makes it challenging to conduct uniform
clinical trials and stratify patient populations accurately. This complexity
could impede the development of targeted therapies, as a clear understanding of
the disease spectrum is crucial for designing effective interventions. Thus,
addressing the diagnostic intricacies of MSA is essential to unlock the full
growth potential of the Global Multiple System Atrophy Market.
High
Research and Development Risks
The Global Multiple System Atrophy (MSA)
Market faces hindrances in growth due to the high research and development
(R&D) risks associated with addressing this complex neurodegenerative
disorder. Developing effective treatments for MSA demands substantial
investment in R&D, often with uncertain outcomes. The intricate nature of
the disease, coupled with the lack of comprehensive understanding of its
underlying mechanisms, amplifies the inherent risks in drug development. Investors
and pharmaceutical companies may be deterred by the considerable uncertainty in
achieving successful outcomes during clinical trials. High R&D risks
contribute to extended timelines, increased costs, and the potential for
failures at various stages of development, posing financial challenges and
diminishing the attractiveness of MSA-focused projects. Furthermore, the
absence of clear biomarkers and standardized diagnostic criteria for MSA adds
an additional layer of complexity, making it difficult to measure treatment
efficacy accurately. This uncertainty may discourage stakeholders from
committing resources to projects with unpredictable outcomes. Mitigating these
high R&D risks requires collaborative efforts, increased understanding of
disease pathology, and innovative approaches, as overcoming these challenges is
essential for unlocking the growth potential of the Global Multiple System
Atrophy Market.
Key Market Trends
Personalized
Medicine and Precision Therapeutics
Personalized medicine and precision
therapeutics are poised to drive significant growth in the Global Multiple
System Atrophy (MSA) Market. As advancements in medical research continue,
there is a growing emphasis on tailoring treatments to the unique genetic,
molecular, and clinical characteristics of individual patients. This approach
allows for more targeted interventions, optimizing therapeutic outcomes for
those afflicted with MSA. By leveraging personalized medicine, pharmaceutical
companies can develop treatments that address specific subtypes or variations
within the MSA patient population. In May 2023, Theravance Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This designation highlights the potential of ampreloxetine as a targeted therapeutic option for a rare and underserved condition, aligning with the growing trend of personalized medicine and precision therapeutics. By focusing on specific patient populations and conditions like nOH in MSA, therapies like ampreloxetine reflect a shift toward more tailored, effective treatments that address the unique needs of individuals, improving outcomes and advancing the field of precision medicine.
Precision therapeutics, guided by biomarker
identification and genetic profiling, enable the design of therapies that are
not only more effective but also have fewer side effects, enhancing overall
patient quality of life. The implementation of personalized medicine strategies
in MSA research and drug development enhances the efficiency of clinical
trials, as patient cohorts can be more precisely defined based on their genetic
and molecular profiles. This not only expedites the approval process but also
fosters a more favorable regulatory environment. In essence, the integration of
personalized medicine and precision therapeutics is poised to revolutionize the
Global Multiple System Atrophy Market, offering tailored solutions that not
only address the complexities of the disease but also pave the way for more
successful and efficient therapeutic interventions.
Rise
of Digital Health Solutions
The ascent of digital health solutions
is set to be a driving force in the growth of the Global Multiple System
Atrophy (MSA) Market. Advanced technologies, such as telemedicine, remote
monitoring, and digital diagnostics, are transforming the landscape of
healthcare delivery, providing novel avenues for MSA management. Digital health
solutions offer the potential to enhance patient care through remote monitoring
of symptoms, facilitating real-time data collection and analysis. This not only
enables healthcare professionals to gain deeper insights into the progression of
MSA but also allows for more proactive and personalized interventions. Telehealth
platforms create opportunities for improved patient engagement, enabling
individuals with MSA to access specialized care remotely. This not only
addresses geographical barriers but also enhances the overall efficiency of
healthcare delivery. Moreover, the integration of digital health tools in
clinical trials enhances the precision and reliability of data collection,
expediting the research and development process for new MSA treatments. As the
healthcare industry increasingly embraces digital solutions, the Global
Multiple System Atrophy Market stands to benefit from heightened efficiency,
improved patient outcomes, and accelerated innovation in the quest for
effective therapies.
Segmental Insights
Diagnosis Insights
Based
on Diagnosis, the Magnetic Resonance Imaging (MRI) emerged
as the fastest growing segment in the global market for Multiple System Atrophy
during the forecast period.
MRI provides non-invasive, high-resolution imaging that is
essential for diagnosing MSA, allowing healthcare professionals to detect
structural changes and brain atrophy associated with the condition. Given that
MSA affects multiple brain regions, MRI’s ability to capture these changes in
detail makes it a critical tool for accurate diagnosis. Advances in MRI
technology, such as enhanced imaging quality and faster scan times, are driving
its increased use in diagnosing MSA. New MRI techniques like functional MRI
(fMRI) and diffusion tensor imaging (DTI) offer greater sensitivity in
detecting early brain changes, which is particularly valuable for
neurodegenerative diseases like MSA. MRI is often used in conjunction with
other diagnostic methods, supporting more accurate and comprehensive diagnoses.
Combined with clinical assessments, MRI helps differentiate MSA from other
neurodegenerative diseases, leading to more reliable diagnoses and improved
patient outcomes. As awareness of MSA grows, there is a stronger focus on early
detection to enable more effective treatment. MRI is crucial in identifying
brain abnormalities in the early stages of MSA, facilitating earlier
intervention and better management. As a result, the MRI segment in the MSA
market is experiencing significant growth, driven by its pivotal role in the
accurate, early, and non-invasive diagnosis of the disease.
End User Insights
Based
on End User, Hospitals emerged as the dominating segment in the global market
for Multiple System Atrophy in 2024. Hospitals are equipped with
state-of-the-art diagnostic technologies, including MRI, PET scans, and other
imaging tools, essential for the accurate diagnosis of MSA. Furthermore, they
house specialized departments such as neurology and radiology, offering expert
knowledge in managing neurodegenerative conditions. Given that MSA is a
complex, multi-system disorder, effective treatment requires a
multidisciplinary approach. Hospitals are well-positioned to provide this level
of care, with access to a wide range of specialists, including neurologists,
cardiologists, and physiotherapists, ensuring holistic management of the
disease across various symptoms and stages.
In
addition, hospitals have the infrastructure to administer advanced therapies
and conduct clinical trials for MSA, offering access to specialized treatments,
experimental therapies, and investigational drugs. They also have the capacity
to monitor patient progress using comprehensive clinical tools. Many hospitals,
particularly large academic centers, are heavily involved in research and
clinical trials, which play a key role in developing new treatments for MSA,
offering patients access to cutting-edge therapies that may not be available in
smaller outpatient settings. MSA patients may experience sudden health
complications or rapid disease progression, necessitating immediate medical
attention. Hospitals provide the critical emergency and inpatient services
required to manage these acute needs, services that smaller centers may lack.
As a result, hospitals possess the resources, expertise, and facilities
required to effectively address the complex needs of MSA patients, making them
the leading end-users in the market.
Download Free Sample Report
Regional Insights
Based on Region, North America emerged as the dominant region in the Global Multiple System Atrophy Market in 2024. North America, particularly the United States, boasts a highly advanced healthcare system equipped with cutting-edge diagnostic tools, treatment facilities, and research institutions. This robust infrastructure plays a pivotal role in the efficient diagnosis and management of complex diseases like MSA. The U.S. Food and Drug Administration (FDA) offers a well-structured regulatory environment that facilitates the approval of new therapies and diagnostic tools, encouraging the development of innovative treatments for MSA and other neurodegenerative disorders, thus ensuring faster access to these therapies for patients.
In January 2025, with support from the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH), the implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act will be led. Signed into law on July 2, 2024, this legislation aims to establish a Federal Advisory Council on Parkinson's Research, Care, and Services, and calls for the creation of a comprehensive national plan to address Parkinson's disease and other neurodegenerative Parkinsonisms, such as MSA, corticobasal degeneration, progressive supranuclear palsy, and Parkinson's-related dementia. North America is home to numerous leading medical centers and academic hospitals, which are actively engaged in clinical trials for new MSA therapies and technologies. This enables regional patients to access the latest advancements in treatment, further propelling market growth. The region’s aging population is also contributing to a rising incidence of neurodegenerative diseases like MSA, leading to greater demand for specialized care and treatments, thereby strengthening North America's position in the global market. Together, these factors make North America the dominant player in the MSA market, with its strong healthcare infrastructure, substantial research investments, and increasing need for innovative diagnostic and therapeutic solutions.
Recent Development
- In
January 2025, Alterity Therapeutics, a biotechnology company, issued a letter
to shareholders announcing the completion of a 12-month, double-blind Phase 2
clinical trial of ATH434 in early-stage Multiple System Atrophy (MSA). The
company anticipates a topline data readout in late January or early February.
In July 2024, Alterity reported encouraging preliminary results from an
open-label biomarker study in individuals with advanced MSA. The open-label
study showed that patients treated with ATH434 for six months had stable or
improved clinical outcomes, with biomarker data supporting these clinical
benefits. This provides strong evidence for ATH434’s potential to slow the
progression of this aggressive disease. In addition to clinical progress,
Alterity continues to generate promising data in MSA and other neurological
diseases. Last year, the company presented the BioMUSE Natural History study,
conducted in collaboration with Professor Daniel Claassen’s neuroimaging group
at Vanderbilt University Medical Center, provided valuable insights into MSA
progression and led to the development of a new imaging biomarker for assessing
brain volume in MSA-affected regions. With topline data from both Phase 2 MSA
trials expected this year, 2025 is set to be a pivotal year for Alterity.
- In
November 2024, Amprion, a global leader in advancing the diagnosis of
neurodegenerative disorders through seed amplification testing, announced the
publication of a study in The Lancet Neurology. The research
demonstrated the capability of the synuclein seed amplification assay (synSAA)
to distinguish between Type 1 and Type 2 synuclein seeds, addressing the
critical need for accurate diagnosis of multiple system atrophy (MSA). By
analyzing cerebrospinal fluid (CSF), synSAA can identify the type of synuclein
neuropathology in living patients. These findings mark a significant step
forward in overcoming diagnostic challenges in synucleinopathies, enabling
earlier interventions and potentially improving patient outcomes. Additionally,
the results pave the way for further testing and validation of synSAA, bringing
this innovative diagnostic tool closer to clinical application.
- In
October 2024, AskBio announced 11 presentations at the 31st Annual Meeting of
the European Society of Gene and Cell Therapy. These included two oral
presentations and nine posters, showcasing progress in AskBio’s clinical and
preclinical pipeline, as well as advancements in its manufacturing
technologies. Alongside recent clinical program milestones, the presentations
underscore AskBio’s commitment to enhancing its end-to-end capabilities and its
goal of delivering breakthrough therapies. The company’s clinical-stage
portfolio spans neuromuscular, central nervous system, cardiovascular, and
metabolic diseases, with investigational therapeutics in development for
conditions including congestive heart failure, multiple system atrophy,
Parkinson’s disease, and Pompe disease.
- In
October 2024, the experimental vaccine UB-312 demonstrated early potential in
treating Parkinson's disease (PD) and multiple system atrophy (MSA), according
to results from a Phase 1b study. The vaccine was shown to be safe and
well-tolerated in participants with MSA and PD, and it successfully generated
detectable antibodies in both serum and cerebrospinal fluid. Dr. Patricio
Millar Vernetti, MD, a research instructor in the Department of Neurology at
NYU Grossman School of Medicine, New York City, led the study. These findings
were presented at the 2024 International Congress of Parkinson’s Disease and
Movement Disorders (MDS).
Key Market Players
- Biohaven Ltd.
- Theravance Biopharma
- Sumitomo Dainippon Pharma Co., Ltd.
- Alterity Therapeutics
- AstraZeneca plc.
- Biogen
- Merck & Co., Inc.
- Neuropore Therapies, Inc.
- WaveBreak Therapeutics
- Newron Pharmaceuticals SPA.
|
By
Diagnosis
|
By
Age
|
By
End User
|
By Region
|
- Magnetic Resonance
Imaging (MRI)
- Positron Emission
Tomography (PET)
- Single Photon
Emission Computed Tomography (SPECT)
- Tilt Table Test
- Others
|
|
- Hospitals
- Ambulatory Surgical Centers
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Multiple System Atrophy Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
·
Multiple System Atrophy Market, By Diagnosis:
o Magnetic Resonance Imaging (MRI)
o Positron Emission Tomography (PET)
o Single Photon Emission Computed
Tomography (SPECT)
o Tilt Table Test
o Others
·
Multiple System Atrophy Market, By Age:
o Pediatric
o Adults
o Geriatric
·
Multiple System Atrophy Market, By End User:
o Hospitals
o Ambulatory Surgical Centers
o Others
·
Multiple System Atrophy Market, By Region:
§
United
States
§
Canada
§
Mexico
§
France
§
United
Kingdom
§
Italy
§
Germany
§
Spain
§
China
§
India
§
Japan
§
Australia
§
South
Korea
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§
South
Africa
§
Saudi
Arabia
§
UAE
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Global Multiple System Atrophy
Market.
Available Customizations:
Global Multiple System Atrophy market report with the given market data,
TechSci Research offers customizations according to a company's specific
needs. The following customization options are available for the report:
Company Information
·
Detailed
analysis and profiling of additional market players (up to five).
Global Multiple System Atrophy Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]